Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors

Anderson, Redmond‐Craig; Velez, Erik; Desai, Bhushan; Jadvar, Hossein

doi:10.1007/s13139-020-00677-0

Cited by 12 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…68 Ga-DOTA-SSA PET/CT often led to treatment changes involving PRRT 27,28,31,33,37,39,40,43,44,46,48,49 ; surgery 26–31,33–38,40,42–44,46–49 ; and chemotherapy, SSA therapy, or other medical treatment 27,28,31,34,35,37,40,43,44,46–49 by providing additional information not present on previous imaging. The most prominent form of change in 8/9 28,31,33,34,39,40,43,49 studies that included patients who previously underwent functional imaging tests (eg, 111 In-penetreotide scintigraphy, 18 F-FDG PET/CT) was PRRT. The other study 45 did not provide details on the types of management change.…”

Section: Resultsmentioning

confidence: 99%

“…This was an article in which patients with multiple endocrine neoplasia type 1 (MEN1) were analyzed. 68 Ga-DOTA-SSA PET/CT often led to treatment changes involving PRRT 27,28,31,33,37,39,40,43,44,46,48,49 ; surgery [26][27][28][29][30][31][33][34][35][36][37][38]40,[42][43][44][46][47][48][49] ; and chemotherapy, SSA therapy, or other medical treatment 27,28,31,34,35,37,40,43,44,[46][47][48][49] by providing additional information not present on previous imaging. The most prominent form of change in 8/9 28,31,33,…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors

et al. 2022

View full text Add to dashboard Cite

Purpose: The aim of this study was to identify and evaluate the role of 68 Ga-DOTA-somatostatin analog (SSA) PET/CT in guiding treatment for patients with neuroendocrine tumors (NETs) based on published literature, with specific focus on the ability of PET/CT to impact clinical management and predict peptide receptor radionuclide therapy (PRRT) response. Patients and Methods: A systematic literature search of articles up to December 2021 was performed using PubMed and Scopus. Eligible studies included ≥10 patients with confirmed or suspected NETs who had undergone pretreatment staging 68 Ga-DOTA-SSA PET/CT. A meta-analysis using the random-effects model was conducted to determine the overall change in management after PET/CT, whereas PET/CT-derived parameters that correlated with PRRT outcome were summarized from studies that assessed its predictive capabilities. Results: A total of 39 studies were included in this systemic review, of which 2266 patients from 24 studies were included for meta-analysis. We showed that PET/CT resulted in a change in clinical management in 36% (95% confidence interval, 31%-41%; range, 3%-66%) of patients. Fifteen studies consisting of 618 patients examined the prognostic ability of 68 Ga-DOTA-SSA PET/CT for PRRT. Of those, 8 studies identified a higher pretreatment SUV to favor PRRT, and 4 identified PET-based radiomic features for somatostatin receptor heterogeneity to be predictive of PRRT response. Conclusions: Along with its diagnostic abilities, 68 Ga-DOTA-SSA PET/CT can impact treatment decision-making and may predict PRRT response in patients with NETs. More robust studies should be conducted to better elucidate the prognostic role of somatostatin receptor PET/CT in optimizing treatment for clinical outcome.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition, high-volume production of 68 Ga may aid in the imaging of other organ studies. For instance, the FDA-approved 68 Ga-DOTATATE PET/CT and 68 Ga-DOTATOC PET/CT are the preferred imaging modalities for initial diagnosis, disease extent evaluation, and selection of patients for peptide receptor radionuclide therapy (PRRT), in patients with neuroendocrine tumors (NETs) [18] , [19] , [20] . 68 Ga ventilation and perfusion PET/CT imaging is an upcoming study for pre-operative and radiotherapy planning in patients with lung cancer [ [21] , [22] ].…”

Section: Discussionmentioning

confidence: 99%

Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial

Martinez¹,

Subramanian²,

Castellanos³

et al. 2023

Translational Oncology

View full text Add to dashboard Cite

“…Positron emission tomography (PET) is a biomedical imaging technique that allows for the quantitative evaluation of the metabolic processes and physiological activities of living bodies by visualizing the distribution of radiolabeled tracers [1][2][3][4]. To effectively detect the annihilation photons with relatively high energy of 511 keV, PET scanners are typically ring-shaped and consist of scintillation crystal-based radiation detector modules.…”

Section: Introductionmentioning

confidence: 99%

Silicon photomultiplier signal readout and multiplexing techniques for positron emission tomography: a review

Park

Lee

2022

Biomed. Eng. Lett.

View full text Add to dashboard Cite

In recent years, silicon photomultiplier (SiPM) is replacing the photomultiplier tube (PMT) in positron emission tomography (PET) systems due to its superior properties, such as fast single-photon timing response, small gap between adjacent photosensitive pixels in the array, and insensitivity to magnetic fields. One of the technical challenges when developing SiPM-based PET systems or other position-sensitive radiation detectors is the large number of output channels coming from the SiPM array. Therefore, various signal multiplexing methods have been proposed to reduce the number of output channels and the load on the subsequent data acquisition (DAQ) system. However, the large PN-junction capacitance and quenching resistance of the SiPM yield undesirable resistance–capacitance delay when multiple SiPMs are combined, which subsequently causes the accumulation of dark counts and signal fluctuation of SiPMs. Therefore, without proper SiPM signal handling and processing, the SiPMs may yield worse timing characteristics than the PMTs. This article reviews the evolution of signal readout and multiplexing methods for the SiPM. In this review, we focus primarily on analog electronics for SiPM signal multiplexing, which allows for the reduction of DAQ channels required for the SiPM-based position-sensitive detectors used in PET and other radiation detector systems. Although the applications of most technologies described in the article are not limited to PET systems, the review highlights efforts to improve the physical performance (e.g. spatial, energy, and timing resolutions) of PET detectors and systems.

show abstract

Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors

Cited by 12 publications

References 28 publications

The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors

The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors

Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial

Silicon photomultiplier signal readout and multiplexing techniques for positron emission tomography: a review

Contact Info

Product

Resources

About